<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072421</url>
  </required_header>
  <id_info>
    <org_study_id>DPH00-Cohort</org_study_id>
    <nct_id>NCT02072421</nct_id>
  </id_info>
  <brief_title>The MASS COMM Post-Randomization Phase Cohort Study</brief_title>
  <official_title>A Prospective, Multi-center, Non-Randomized, Single-arm, Open-label Study of Percutaneous Coronary Intervention in Community Hospitals Without Cardiac Surgery-On-Site</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baim Institute for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brockton Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Good Samaritan Hospital Medical Center, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwood Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holy Family Hospital, Methuen, MA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lawrence General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lowell General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Melrose Wakefield Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Metro West Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saints Memorial Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South Shore Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baim Institute for Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the Post-Randomization Phase Cohort Study is to continue to assess&#xD;
      the safety of non-emergency PCI performed at hospitals without cardiac surgery on-site in&#xD;
      patients with myocardial ischemia (other than ST-segment elevation myocardial infarction&#xD;
      [STEMI]).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MASS COMM Post-Randomization Phase Cohort Study (&quot;Cohort Study&quot; is a prospective,&#xD;
      multi-center, single-arm study of non-emergency PCI performed at non-SOS hospitals in&#xD;
      patients with myocardial ischemia (other than STEMI). The Cohort Study is designed to allow&#xD;
      non-SOS hospitals to continue to perform non-emergency PCI after enrollment to the MASS COMM&#xD;
      trial is completed and before the 30-day and 12-month results are available.&#xD;
&#xD;
      Specifically, all eligible subjects, after enrollment to the MASS COMM randomized controlled&#xD;
      trial is completed and before the final results are available and a decision is reached by&#xD;
      the MA-DPH, will be consented and enrolled into this Cohort Study. Subjects will be followed&#xD;
      through 30 days post procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>30-days</time_frame>
    <description>MACE is a composite of all cause mortality, myocardial infarction (Q wave and non-Q wave), repeat coronary revascularization (of the target vessel or non-target vessel) by either percutaneous or coronary artery bypass graft (CABG) methods, or stroke, at 30-days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>all-cause mortality through 30 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>Stroke through 30 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>Repeat coronary revascularization including emergency or urgent revascularization through 30 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Vascular Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Major vascular complications, including access site complications and major bleeding events requiring transfusion,through 30 days post-procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2879</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Non-SOS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI</intervention_name>
    <arm_group_label>Non-SOS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Candidates for this study must meet ALL of the following criteria:&#xD;
&#xD;
          -  Subject is at least 18 years old.&#xD;
&#xD;
          -  Subject requires single- or multi-vessel percutaneous coronary intervention (PCI) of&#xD;
             de novo or restenotic target lesion (including in-stent restenotic lesions). N.B.&#xD;
             staged procedure will not be considered to meet the endpoint component of repeat&#xD;
             revascularization if either of the following pre-catheterization procedure qualifying&#xD;
             clinical laboratory values are met:&#xD;
&#xD;
               -  eGFR is less than 60 ml/min or&#xD;
&#xD;
               -  creatinine is greater than 1.5 mg/dl&#xD;
&#xD;
          -  Subject's lesion(s) is (are) amenable to stent treatment with currently available&#xD;
             FDA-approved bare metal or drug eluting stents.&#xD;
&#xD;
          -  Subject is an acceptable candidate for non-emergency, urgent or emergency CABG.&#xD;
&#xD;
          -  Subject has clinical evidence of ischemic heart disease in terms of a positive&#xD;
             functional study, or documented symptoms.&#xD;
&#xD;
          -  Documented stable angina pectoris [Canadian Cardiovascular Society Classification&#xD;
             (CCS) 1, 2, 3, or 4], unstable angina pectoris with documented ischemia (Braunwald&#xD;
             Class IB-C, IIB-C, or IIIB-C), non-ST segment elevation myocardial infarction, or&#xD;
             documented silent ischemia.&#xD;
&#xD;
          -  Subject and the treating physician agree that the subject will comply with all&#xD;
             follow-up evaluations.&#xD;
&#xD;
          -  Subject has been informed of the nature and purpose of the study and agrees to its&#xD;
             provisions and has provided written informed consent as approved by the Institutional&#xD;
             Review Board/Ethics Committee of the respective clinical site.&#xD;
&#xD;
        Angiographic Inclusion Criteria&#xD;
&#xD;
          -  The target lesion(s) is (are) de novo or restenotic (including in-stent restenotic)&#xD;
             native coronary artery lesion(s) with greater or equal to 50 and less than 100%&#xD;
             stenosis (visual estimate), or the target lesion is an acute (less than 1 month) total&#xD;
             occlusion as evidenced by clinical symptoms.&#xD;
&#xD;
          -  If Fractional Flow Reserve (FFR) is measured, target lesion(s) has (have) evidence of&#xD;
             a hemodynamically significant stenosis determined by FFR measurement (FFR less than or&#xD;
             equal to 0.8).&#xD;
&#xD;
          -  Target lesions(s) is (are) located in an infarct (if not treated with primary PCI) or&#xD;
             non-infarct-related artery with a 70% or greater stenosis (by visual estimate) greater&#xD;
             than 72 hours following the STEMI.&#xD;
&#xD;
        Lesions treated with PCI greater than 72 hours following STEMI would be subject to the same&#xD;
        protocol inclusion/exclusion criteria listed above and below with the exception that a&#xD;
        target lesion of 70% or greater stenosis may be treated with or without symptoms or&#xD;
        abnormal stress test).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from participation in the Cohort Study (and non-emergency PCI may&#xD;
        not be performed in these patients at the non-SOS site) if ANY of the following conditions&#xD;
        apply:&#xD;
&#xD;
          -  The patient is pregnant or breastfeeding.&#xD;
&#xD;
          -  Evidence of ST segment elevation myocardial infarction within 72 hours of the intended&#xD;
             treatment on infarct related or non-infarct related artery.&#xD;
&#xD;
          -  Cardiogenic shock on presentation or during current hospitalization.&#xD;
&#xD;
          -  Left ventricular ejection fraction less than 20%.&#xD;
&#xD;
          -  Known allergies to: aspirin, clopidogrel (Plavix), prasugrel (Effient), and&#xD;
             ticlopidine (Ticlid), heparin, bivalirudin, stainless steel, or contrast agent (which&#xD;
             cannot be adequately premedicated).&#xD;
&#xD;
          -  A platelet count less than 75,000 cells/mm3 or greater than 700,000 cells/mm3 or a WBC&#xD;
             less than 3,000 cells/mm3.&#xD;
&#xD;
          -  Acute or chronic renal dysfunction (creatinine less than 2.5 mg/dl or less than&#xD;
             150Âµmol/L).&#xD;
&#xD;
          -  Subject is currently participating in an investigational drug or device study that has&#xD;
             not completed the primary endpoint or that clinically interferes with the current&#xD;
             study endpoints. (Note: Trials requiring extended follow-up for products that were&#xD;
             investigational, but have since become commercially available, are not considered&#xD;
             investigational trials).&#xD;
&#xD;
          -  Prior participation in the MASS-COMM Trial, unless the patient has completed the&#xD;
             12-month follow-up for the Trial, and/or prior participation in the Cohort Study,&#xD;
             unless the patient has completed the 30-day follow-up for the Cohort Study.&#xD;
&#xD;
          -  Within 30 days prior to the index Cohort Study procedure, the subject has undergone a&#xD;
             previous coronary interventional procedure of any kind. Note: This exclusion criterion&#xD;
             does not apply to post-STEMI patients.&#xD;
&#xD;
          -  Stroke or transient ischemic attack within the prior 3 months.&#xD;
&#xD;
          -  Active peptic ulcer or upper GI bleeding within the prior 3 months.&#xD;
&#xD;
          -  Subject has active sepsis.&#xD;
&#xD;
          -  Unprotected left main coronary artery disease (stenosis greater than 50%).&#xD;
&#xD;
          -  Subject has evidence of a hemodynamically insignificant stenosis determined by FFR&#xD;
             measurement (FFR greater than 0.8).&#xD;
&#xD;
          -  In the investigator's opinion, subject has a co-morbid condition(s) that could limit&#xD;
             the subject's ability to participate in the study or comply with follow-up&#xD;
             requirements or impact the scientific integrity of the study.&#xD;
&#xD;
        Angiographic Exclusion Criteria&#xD;
&#xD;
          -  Subject has normal or insignificant coronaries (i.e., coronary lesion(s) less than 50%&#xD;
             stenosis).&#xD;
&#xD;
          -  Any target vessel has evidence of:&#xD;
&#xD;
               1. excessive thrombus (e.g., requires target vessel thrombectomy)&#xD;
&#xD;
               2. tortuosity (greater than 60 degree angle) that makes it unsuitable for proper&#xD;
                  stent delivery and deployment,&#xD;
&#xD;
               3. heavy calcification.&#xD;
&#xD;
          -  Any target lesion requires treatment with a device other than PTCA prior to stent&#xD;
             placement (e.g. but not limited to, directional coronary atherectomy, excimer laser,&#xD;
             rotational atherectomy, etc.).&#xD;
&#xD;
          -  Any lesion that is located in a saphenous vein graft, however, lesions located within&#xD;
             the native vessel but accessed through the graft are eligible.&#xD;
&#xD;
          -  The target vessel is in a &quot;last remaining&quot; epicardial vessel (e.g., &gt;2 non-target&#xD;
             epicardial vessels and the bypass grafts to these territories [if present] are totally&#xD;
             occluded).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice K Jacobs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University School of Medicine , Boston Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Mauri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon-Lise Normand, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Medical School (HMS and HSDM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Good Samaritan Medical Center</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brockton Hospital</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrowest Medical Center</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <zip>01702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence General Hospital</name>
      <address>
        <city>Lawrence</city>
        <state>Massachusetts</state>
        <zip>01842</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saints Memorial Medical Center</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowell General Hospital</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melrose-Wakefield Hospital</name>
      <address>
        <city>Melrose</city>
        <state>Massachusetts</state>
        <zip>02176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Family Hospital</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwood Hospital</name>
      <address>
        <city>Norwood</city>
        <state>Massachusetts</state>
        <zip>02062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Shore Hospital</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <results_first_submitted>June 6, 2014</results_first_submitted>
  <results_first_submitted_qc>June 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2014</results_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PCI at Hospitals Without On-Site Cardiac Surgery</title>
          <description>PCI at a hospital without on-site cardiac surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2879"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2489"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="390"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PCI at Hospitals Without On-Site Cardiac Surgery</title>
          <description>PCI at a hospital without on-site cardiac surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2879"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.92" spread="11.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Cardiac Event (MACE)</title>
        <description>MACE is a composite of all cause mortality, myocardial infarction (Q wave and non-Q wave), repeat coronary revascularization (of the target vessel or non-target vessel) by either percutaneous or coronary artery bypass graft (CABG) methods, or stroke, at 30-days.</description>
        <time_frame>30-days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCI at Hospitals Without On-Site Cardiac Surgery</title>
            <description>Assigned to PCI at a hospital without on-site cardiac surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event (MACE)</title>
          <description>MACE is a composite of all cause mortality, myocardial infarction (Q wave and non-Q wave), repeat coronary revascularization (of the target vessel or non-target vessel) by either percutaneous or coronary artery bypass graft (CABG) methods, or stroke, at 30-days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2879"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-Cause Mortality</title>
        <description>all-cause mortality through 30 days post-procedure</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCI at Hospitals Without On-Site Cardiac Surgery</title>
            <description>Assigned to PCI at a hospital without on-site cardiac surgery</description>
          </group>
        </group_list>
        <measure>
          <title>All-Cause Mortality</title>
          <description>all-cause mortality through 30 days post-procedure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2879"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke</title>
        <description>Stroke through 30 days post-procedure</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCI at a Hospital Without On-site Cardiac Surgery</title>
            <description>PCI at a hospital without on-site cardiac surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke</title>
          <description>Stroke through 30 days post-procedure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2879"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Revascularization</title>
        <description>Repeat coronary revascularization including emergency or urgent revascularization through 30 days post-procedure</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCI at a Hospital Without On-site Cardiac Surgery</title>
            <description>PCI at a hospital without on-site cardiac surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Revascularization</title>
          <description>Repeat coronary revascularization including emergency or urgent revascularization through 30 days post-procedure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2879"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Vascular Complications</title>
        <description>Major vascular complications, including access site complications and major bleeding events requiring transfusion,through 30 days post-procedure.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCI at a Hospital Without On-site Cardiac Surgery</title>
            <description>PCI at a hospital without on-site cardiac surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Major Vascular Complications</title>
          <description>Major vascular complications, including access site complications and major bleeding events requiring transfusion,through 30 days post-procedure.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2879"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and other adverse events were not collected in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>PCI at Hospitals Without On-Site Cardiac Surgery</title>
          <description>PCI at a hospital without on-site cardiac surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Priscilla Driscoll-Shemp</name_or_title>
      <organization>Harvard Clinical Research Institute</organization>
      <phone>617-307-5200</phone>
      <email>priscilla.driscoll-shempp@hcri.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

